This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:** 

Claim 1 (currently amended): A preparation comprising a homeopathic potency of purified

insulin-like growth factor-1 (IGF-1) suitable for oral administration, wherein the purified insulin-

like growth factor-1 (IGF-1) has a homeopathic potency selected from the group consisting of:

6X, 6C, 15X, 12C, 30C, 100C, 200C, and 1M (1000C) concentration of said purified insulin-like

growth factor 1 is less than 1 x 10<sup>-6</sup> molar, and wherein said homeopathic potency is formulated

in a liquid or solid formulation.

Claim 2 (previously presented): A preparation as recited in claim 1 additionally comprising at

least one component selected from the group consisting of: a vitamin, a mineral, an amino acid,

carnitine, CoQ10, vitamin K, vitamin E, Ginko Biloba, Phosphadityl Serine, an Omega 3 oil, flax

seed, fish oil, polyamines, alpha hydroxy, glycolytic acid, and DHA.

Claim 9 (canceled).

Claim 10 (canceled).

Claim 11 (previously presented): A preparation as recited in claim 1, wherein the purified

insulin-like growth factor-1 is a recombinant human protein.

Claim 13 (currently amended): A preparation as recited in claim 4 30 wherein the purified

insulin-like growth factor-1 has a homeopathic potency selected from the group consisting of:

6X, 6C, 15X, 12C, 30C, 100C, 200C, and 1M (1000C).

Claim 14 (previously presented): A preparation as recited in claim 1, additionally comprising a

homeopathic potency of a substance selected from the group consisting of: a fibroblast growth

factor (FGF), a platelet-derived growth factor (PDGF), an interleukin-2, and a hepatocyte growth

2/10

factor.

Claim 15 (previously presented): A preparation as recited in claim 1 comprising a combination

potency formulation having at least two homeopathic potencies.

Claim 16 (previously presented): A preparation as recited in claim 15, wherein the combination

potency formulation comprises 6X and 12C homeopathic potencies.

Claim 17 (previously presented): A preparation as recited in claim 15, wherein the combination

potency formulation comprises 6C, 100C, and 200C homeopathic potencies.

Claim 18 (previously presented): A preparation as recited in claim 15, wherein the combination

potency formulation comprises 6C and 1M homeopathic potencies.

Claim 19 (previously presented): A preparation as recited in claim 1, additionally comprising one

or more traditional homeopathics selected from the group consisting of: arsenicum, pulseatilla,

aconite, hypericum, and metabolic sarcodes.

Claim 20 (previously presented): A preparation as recited in claim 1, further comprising a

homeopathic potency of purified growth hormone.

Claim 21 (previously presented): A preparation as recited in claim 1, wherein the homeopathic

potency of IGF-1 is 30C.

Claim 22 (previously presented): A preparation as recited in claim 1, wherein the homeopathic

potency of IGF-1 is 1M.

Claim 23 (previously presented): A preparation as recited in claim 1, wherein the homeopathic

potency of IGF-1 is 6C.

3/10

Application no. 10/001,367

Attorney docket No. 20371.0004c4

Response to Office Action mailed June 27, 2006

24. (Previously allowed): A preparation comprising a homeopathic potency of purified

insulin-like growth factor-1 (IGF-1) suitable for oral administration, wherein the concentration of

purified insulin-like growth factor-1 is less than 1x 10<sup>-6</sup> molar, and the preparation additionally

comprises homeopathic potencies of PDGF and TGF<sub>81</sub>.

25. (Previously allowed): A preparation as recited in claim 24, wherein the IGF-1, PDGF and

 $TGF_{B1}$  homeopathic potencies are formulated using human recombinant proteins.

26. (Previously allowed): A preparation as recited in claim 24, wherein the IGF-1, PDGF and

 $TGF_{\beta 1}$  homeopathic potencies are all 30C + 1M potencies.

27. (Previously allowed): A preparation comprising a homeopathic potency of purified

insulin-like growth factor-1 (IGF-1) suitable for oral administration, wherein the concentration of

said purified insulin-like growth factor-1 is less than 1x 10<sup>-6</sup> molar, and the preparation

additionally comprises homeopathic potencies of GM-CSF, PDGF<sub>BB</sub> and TGF<sub>B1</sub>.

28. (Previously allowed): A preparation as recited in claim 27, wherein the IGF-1, GM-CSF,

PDGF<sub>BB</sub> and TGF<sub>\beta1</sub> homeopathic potencies are formulated using human recombinant proteins.

Claim 29 (canceled).

Claim 30 (currently amended): A preparation comprising a homeopathic potency of purified

insulin-like growth factor-1 (IGF-1) suitable for oral administration, wherein the concentration of

said purified insulin-like growth factor-1 is less than 1 x 10<sup>-6</sup> molar, wherein said homeopathic

potency is impregnated on a solid medium, and as recited in claim 9, wherein the solid medium

is a tablet.

Claim 31 (new): A preparation as recited in claim 30, additionally comprising a homeopathic

potency of a substance selected from the group consisting of: a fibroblast growth factor (FGF), a

platelet-derived growth factor (PDGF), an interleukin-2, and a hepatocyte growth factor.

4/10

Application no. 10/001,367

Attorney docket No. 20371.0004c4

Response to Office Action mailed June 27, 2006

Claim 32 (new): A preparation as recited in claim 30 comprising a combination potency formulation having at least two homeopathic potencies.

Claim 33 (new): A preparation as recited in claim 30, further comprising a homeopathic potency of purified growth hormone.